Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEAYA Biosciences has the GF Score of 50, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes IDEAYA Biosciences
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
IDEAYA Biosciences (STU:30J) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
IDEAYA Biosciences GF Score Related Terms
STU:30J vs PBLS, ELVN, BEAM: GF Score Comparison
For the Biotechnology subindustry, IDEAYA Biosciences's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's GF Score distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's GF Score falls into.
IDEAYA Biosciences (STU:30J) has a GF Score of 50 as of Jul. 16, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on IDEAYA Biosciences and its competitors. This is 47% above median its historical median of 34.00. Over the past decade, IDEAYA Biosciences' GF Score has ranged from 11.00 to 54.00.
Is IDEAYA Biosciences' GF Score too high?
IDEAYA Biosciences' current GF Score of 50 is 47% above median its 10-year median of 34.00. Over the past 10 years, this metric has ranged from a low of 11.00 to a high of 54.00. Overall, IDEAYA Biosciences has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' GF Score compare to PBLS and ELVN?
IDEAYA Biosciences' GF Score of 50 can be compared against companies in the Biotechnology industry. Historically, IDEAYA Biosciences' own GF Score has ranged from 11.00 to 54.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on IDEAYA Biosciences and its competitors. IDEAYA Biosciences's current GF Score is 50, which is 47% above median its own 10-year median of 34.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (STU:30J) is currently considered Possible Value Trap. The stock's GF Value™ is €168.23, compared to a current price of €32.07 — trading 80.9% below its estimated fair value. The current GF Score is 50, which is 47% above median its 10-year median of 34.00. IDEAYA Biosciences' overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For IDEAYA Biosciences (STU:30J), the current GF Score is 50 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEAYA Biosciences (STU:30J) Overvalued in 2026?
Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued.
The current stock price of €32.07 is trading 80.9% below its estimated GF Value™ of €168.23.
GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.
Key valuation signals for STU:30J:
GF Score: 50 (47% above median its 10-year median of 34.00)
GF Value™: €168.23 vs. price of €32.07 (80.9% below fair value)
No single metric tells the full story. See the STU:30J stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
50GF Score
Get the complete analysis for STU:30J
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:30J has been successfully added to your 
